drugset / Trial / NCT01416636

Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)

NCT01416636

Phase 3 Completed 105 enrolled SciPharm SàRL
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to determine the effect on six-minute walking test (6MWT) distance after 24 weeks treatment with subcutaneous (SC) Treprostinil Sodium in patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension.

Timeline

Start
2009-03
Primary completion
2016-11
Completion
2021-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Treprostinil Other / unclassified 3 ng Subcutaneous
Subject Treprostinil Other / unclassified 30 ng Subcutaneous